{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:12:44Z","timestamp":1791277964364,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160097"],"award-info":[{"award-number":["RP160097"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006441","name":"Center for Outcomes Research and Evaluation, Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K07 CA218362"],"award-info":[{"award-number":["K07 CA218362"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007915","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ebiom.2019.09.033","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:27:05Z","timestamp":1571300825000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-9562","authenticated-orcid":false,"given":"Jeremy M.","family":"Schraw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Junco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 24","key":"10.1016\/j.ebiom.2019.09.033_bib0001","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1002\/cncr.30899","article-title":"Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: findings from the CONCORD-2 study","volume":"123","author":"Tai","year":"2017","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ebiom.2019.09.033_bib0002","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ebiom.2019.09.033_bib0003","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.09.033_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-Cell precursor acute lymphoblastic leukemia","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.09.033_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ebiom.2019.09.033_bib0006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-Specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O'Connor","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.09.033_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13148-018-0466-3","article-title":"DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia","volume":"10","author":"Borssen","year":"2018","journal-title":"Clin Epigenetics"},{"issue":"12","key":"10.1016\/j.ebiom.2019.09.033_bib0008","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ebiom.2019.09.033_bib0009","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ebiom.2019.09.033_bib0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the children's oncology group","volume":"118","author":"Matloub","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ebiom.2019.09.033_bib0011","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-Acute lymphoblastic leukemia: a report from children's oncology group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2019.09.033_bib0012","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.09.033_bib0013","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3324\/haematol.2018.204545","article-title":"Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG","volume":"104","author":"Burke","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ebiom.2019.09.033_bib0014","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.31099","article-title":"Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the children's oncology group study AALL1131","volume":"124","author":"Salzer","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ebiom.2019.09.033_bib0015","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.18.00884","article-title":"Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from children's oncology group","volume":"37","author":"McNeer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.09.033_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a000588","article-title":"Metabolomics: an emerging but powerful tool for precision medicine","volume":"1","author":"Clish","year":"2015","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"12","key":"10.1016\/j.ebiom.2019.09.033_bib0017","doi-asserted-by":"crossref","first-page":"e82859","DOI":"10.1371\/journal.pone.0082859","article-title":"Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia","volume":"8","author":"Tiziani","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ebiom.2019.09.033_bib0018","article-title":"SERUM metabolomics of acute lymphoblastic leukaemia and acute myeloid leukaemia for probing biomarker molecules","author":"Musharraf","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ebiom.2019.09.033_bib0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cca.2014.05.022","article-title":"Biomarker identification and pathway analysis by serum metabolomics of childhood acute lymphoblastic leukemia","volume":"436","author":"Bai","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"9","key":"10.1016\/j.ebiom.2019.09.033_bib0020","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1039\/C5MB00237K","article-title":"Metabolomics identifies the intersection of phosphoethanolamine with menaquinone-triggered apoptosis in an in vitro model of leukemia","volume":"11","author":"Dhakshinamoorthy","year":"2015","journal-title":"Mol Biosyst"},{"issue":"6","key":"10.1016\/j.ebiom.2019.09.033_bib0021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clinbiochem.2014.02.013","article-title":"The differential metabolite profiles of acute lymphoblastic leukaemic patients treated with 6-mercaptopurine using untargeted metabolomics approach","volume":"47","author":"Bannur","year":"2014","journal-title":"Clin Biochem"},{"issue":"7","key":"10.1016\/j.ebiom.2019.09.033_bib0022","doi-asserted-by":"crossref","first-page":"e180089","DOI":"10.1001\/jamaoncol.2018.0089","article-title":"Association of cerebrospinal fluid biomarkers of central nervous system injury with neurocognitive and brain imaging outcomes in children receiving chemotherapy for acute lymphoblastic leukemia","volume":"4","author":"Cheung","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.09.033_bib0023","first-page":"12","article-title":"The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation","volume":"12","author":"Reikvam","year":"2016","journal-title":"Metab: Official J Metab Soc"},{"issue":"5","key":"10.1016\/j.ebiom.2019.09.033_bib0024","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1049\/iet-syb:20060077","article-title":"Currency and commodity metabolites: their identification and relation to the modularity of metabolic networks","volume":"1","author":"Huss","year":"2007","journal-title":"IET Syst Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.09.033_bib0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2018-05-850826","article-title":"IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies","volume":"133","author":"Bergaggio","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ebiom.2019.09.033_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114019","article-title":"Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells","volume":"9","author":"Tolstikov","year":"2014","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ebiom.2019.09.033_bib0027","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1074\/jbc.M112.394510","article-title":"Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications","volume":"288","author":"Tan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2019.09.033_bib0028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.12688\/wellcomeopenres.14898.1","article-title":"Metabolic tracing reveals novel adaptations to skeletal muscle cell energy production pathways in response to NAD (+) depletion","volume":"3","author":"Oakey","year":"2018","journal-title":"Wellcome Open Res"},{"issue":"9","key":"10.1016\/j.ebiom.2019.09.033_bib0030","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3109\/10428194.2013.869325","article-title":"The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody","volume":"55","author":"Nahimana","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.ebiom.2019.09.033_bib0031","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.chembiol.2013.09.014","article-title":"Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens","volume":"20","author":"Matheny","year":"2013","journal-title":"Chem Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.09.033_bib0032","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/leu.2017.281","article-title":"Targeting the vulnerability to NAD(+) depletion in B-cell acute lymphoblastic leukemia","volume":"32","author":"Takao","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ebiom.2019.09.033_bib0033","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","volume":"26","author":"Holen","year":"2008","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.ebiom.2019.09.033_bib0034","article-title":"New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology","volume":"3","author":"Roulston","year":"2016","journal-title":"Mol Cell Oncol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419306607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419306607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:55:11Z","timestamp":1762455311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419306607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"alternative-id":["S2352396419306607"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.033","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}